Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis
Yiqing Li, … , Xue Zhang, Yuehai Ke
Yiqing Li, … , Xue Zhang, Yuehai Ke
Published January 10, 2023
Citation Information: J Clin Invest. 2023;133(4):e162870. https://doi.org/10.1172/JCI162870.
View: Text | PDF
Research Article Cell biology

SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis

  • Text
  • PDF
Abstract

SIPRα on macrophages binds with CD47 to resist proengulfment signals, but how the downstream signal of SIPRα controls tumor-infiltrating macrophages (TIMs) is still poorly clarified. Here, we report that the CD47/signal regulatory protein α (SIRPα) axis requires the deneddylation of tyrosine phosphatase SHP2. Mechanistically, Src homology region 2–containing protein tyrosine phosphatase 2 (SHP2) was constitutively neddylated on K358 and K364 sites; thus, its autoinhibited conformation was maintained. In response to CD47-liganded SIRPα, SHP2 was deneddylated by sentrin-specific protease 8 (SENP8), which led to the dephosphorylation of relevant substrates at the phagocytic cup and subsequent inhibition of macrophage phagocytosis. Furthermore, neddylation inactivated myeloid-SHP2 and greatly boosted the efficacy of colorectal cancer (CRC) immunotherapy. Importantly, we observed that supplementation with SHP2 allosteric inhibitors sensitized immune treatment–resistant CRC to immunotherapy. Our results emphasize that the CRC subtype that is unresponsive to immunotherapy relies on SIRPαhiSHP2hiNEDD8lo TIMs and highlight the need to further explore the strategy of SHP2 targeting in CRC therapy.

Authors

Yiqing Li, Hui Zhou, Pan Liu, Dandan Lv, Yichun Shi, Bufu Tang, Jiaqi Xu, Tingting Zhong, Wangting Xu, Jie Zhang, Jianying Zhou, Kejing Ying, Yongchao Zhao, Yi Sun, Zhinong Jiang, Hongqiang Cheng, Xue Zhang, Yuehai Ke

×

Figure 5

CD47/SIRPα signaling requires SHP2 catalytic activity.

Options: View larger image (or click on image) Download as PowerPoint
CD47/SIRPα signaling requires SHP2 catalytic activity.
(A) Schematic sho...
(A) Schematic showing reconstituted target used in this study. (B) Confocal microscopy images showing pTyr and pY397 phosphorated FAK at the phagocytic cup. Scale bar: 10 μm. DiO, DiOC18; DIC, differential interference contrast. (C) Confocal (left) and TIRF (right) images showing pTyr and F-actin (phalloidin) in frustrated phagocytosis. Scale bar: 5 μm. (D) TIRF-STORM showing pTyr is enriched in the phagocytic cup (red arrowheads). Scale bars: 1 μm. (E) Western blot indicating tyrosine phosphorylation profile of subcellular fractionation of BMDMs. (F and G) BMDMs performed frustrated phagocytosis on IgG plus CD47–coated coverslip. pTyr on the membrane was labeled by fluorescence antibody, and the membrane was labeled by wheat germ agglutinin. Representative time-lapse montage of BMDMs, with the pTyr pixel intensity of color-coded values indicated by the color wedge on the right. Scale bars: 5 μm (F). Graph of mean fluorescence intensity of pTyr over time during spreading (cell number = 10) (G). Data are represented as mean ± SD. ****P < 0.0001; NS, P > 0.05. Two-way ANOVA followed by Tukey’s post hoc test (G).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts